As of May 27, 2025, Medivolve Inc (MEDV.NE) reports a ROA (Return on Assets) of -97.59%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Medivolve Inc's ROA (Return on Assets)
Over recent years, Medivolve Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2022-12-31 | -97.59% |
| 2021-12-31 | -11.15% |
| 2020-12-31 | -197.47% |
| 2019-12-31 | -118.16% |
| 2018-12-31 | -15.53% |
This slight downward trend highlights how Medivolve Inc manages its efficiency in using assets to generate earnings over time.
Comparing Medivolve Inc's ROA (Return on Assets) to Peers
To better understand Medivolve Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Medivolve Inc (MEDV.NE) | -97.59% |
| PharmChem Inc (PCHM) | 50.50% |
| Interpace Biosciences Inc (IDXG) | 45.31% |
| Avem Health Partners Inc (FPCG) | 15.46% |
| Nova Leap Health Corp (NLH.V) | 6.16% |
| Global Cord Blood Corp (CO) | 5.87% |
Compared to its competitors, Medivolve Inc's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.